title: VH4-34 encoded antibodies in systemic lupus erythematosus: a specific diagnostic marker that correlates with clinical disease characteristics.
abstract: OBJECTIVE
  To determine the clinical significance of elevated serum levels of VH4-34 encoded antibodies (VH4-34 Ab) with respect to the diagnosis and clinical characteristics of systemic lupus erythematosus (SLE).
  
  
  METHODS
  Ninety-five patients with SLE and 344 controls were studied. The controls included 34 healthy individuals, 282 patients with nonautoimmune diseases, and 28 patients with autoimmune diseases other than SLE. VH4-34 Ab levels were measured by inhibition ELISA using anti-idiotope monoclonal antibody (9G4). SLE disease activity, severity, and damage were assessed by visual analog scales, Systemic Lupus Activity Measure, Lupus Severity of Disease Index, and Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index.
  
  
  RESULTS
  Fifty-two of 95 patients with SLE had elevated levels of VH4-34 Ab compared to 18 of 344 controls (5%), giving a sensitivity of 55% and a specificity of 95% for elevated VH4-34 Ab as a serologic test for SLE. The positive predictive value of elevated VH4-34 under these conditions was 74-85%. In this study, anti-dsDNA was not VH4-34 encoded. Significant correlations between VH4-34 and disease activity and severity indices were observed (r = 0.29-0.50). The relative risk for severe disease in SLE patients with VH4-34 antibody level in the highest tertile compared to the lowest tertile was 5.25. Twenty-five of 29 patients with lupus nephritis and 6 of 6 patients with central nervous system (CNS) lupus had elevated VH4-34 Ab.
  
  
  CONCLUSIONS
  With a specificity of 94-95%, the VH4-34 antibody assay may prove valuable as a confirmatory diagnostic test for SLE. In patients with known SLE, serum VH4-34 Ab levels correlate with overall disease severity and activity, but not damage, and with nephritis and CNS lupus.
authors.affiliation: Division of Immunology and Rheumatology, Stanford University Medical Center, California, USA. ronaldv@rheum.ks.se
authors.forename: R F
authors.initials: RF
authors.lastname: van Vollenhoven
authors.forename: M M
authors.initials: MM
authors.lastname: Bieber
authors.forename: M J
authors.initials: MJ
authors.lastname: Powell
authors.forename: P K
authors.initials: PK
authors.lastname: Gupta
authors.forename: N M
authors.initials: NM
authors.lastname: Bhat
authors.forename: K L
authors.initials: KL
authors.lastname: Richards
authors.forename: S A
authors.initials: SA
authors.lastname: Albano
authors.forename: N N
authors.initials: NN
authors.lastname: Teng
mesh_terms: D000974:Antibodies, Antinuclear / Q000276:immunology; D000918:Antibody Specificity; D001323:Autoantibodies / Q000235:genetics / Q000276:immunology*; D015415:Biomarkers; D018450:Disease Progression; D005260:Female; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000175:diagnosis* / Q000276:immunology; D008297:Male; D012680:Sensitivity and Specificity; D012698:Serologic Tests
chemical_list: D000974:Antibodies, Antinuclear; D001323:Autoantibodies; D015415:Biomarkers